Yahoo · Sep 2, 2026
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia, September 02, 2026--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
AB
NASDAQ · ABCL
AbCellera Biologics Inc.
Healthcare · Biotechnology
$10.46
Down-$0.59 (-5.34%)
Updated Sep 11, 2026, 6:45 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.08B
- P/E ratio
- -7.37
- Dividend yield
- 0.00%
- 52-week range
- $3.22 – $12.58
- Volume
- 4.94M
- Avg. volume
- 4.11M
Price performance
ABCL price history
1M range · 20 trading sessions · Daily adjusted prices
ABCL closed at $10.46 after 20 trading sessions, down 4.65% for the selected period.
- Last close
- $10.46
- Period change
- -4.65%
- Period low
- $10.46
- Period high
- $12.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $10.79 | $11.07 | $10.42 | $10.46 | 4.94M |
| Sep 9, 2026 | $11.37 | $11.45 | $11.01 | $11.05 | 2.41M |
| Sep 8, 2026 | $11.29 | $11.64 | $11.10 | $11.44 | 2.56M |
| Sep 4, 2026 | $11.50 | $11.59 | $11.33 | $11.43 | 2.02M |
| Sep 3, 2026 | $11.58 | $11.82 | $11.26 | $11.57 | 3.29M |
| Sep 2, 2026 | $11.39 | $11.5699 | $10.80 | $11.36 | 3.73M |
| Sep 1, 2026 | $11.24 | $11.52 | $11.05 | $11.28 | 4.25M |
| Aug 31, 2026 | $11.10 | $11.575 | $10.83 | $11.48 | 4.96M |
| Aug 28, 2026 | $12.305 | $12.35 | $11.26 | $11.35 | 5.86M |
| Aug 27, 2026 | $12.25 | $12.5799 | $12.085 | $12.40 | 4.27M |
| Aug 26, 2026 | $12.22 | $12.36 | $12.05 | $12.24 | 5.04M |
| Aug 25, 2026 | $11.00 | $12.50 | $10.99 | $12.50 | 10.7M |
| Aug 24, 2026 | $10.97 | $11.01 | $10.44 | $10.61 | 6.59M |
| Aug 21, 2026 | $11.57 | $11.7999 | $11.14 | $11.32 | 4.55M |
| Aug 20, 2026 | $11.815 | $12.08 | $11.40 | $11.57 | 6.18M |
| Aug 19, 2026 | $11.50 | $12.15 | $11.47 | $12.01 | 10.81M |
| Aug 18, 2026 | $10.795 | $11.515 | $10.70 | $11.12 | 8.2M |
| Aug 17, 2026 | $11.30 | $11.645 | $10.6044 | $11.20 | 7.85M |
| Aug 14, 2026 | $10.84 | $11.50 | $10.47 | $11.38 | 12.38M |
| Aug 13, 2026 | $10.32 | $11.065 | $10.22 | $10.97 | 20.13M |
Latest ABCL news
The latest Smart Investors Daily articles mentioning ABCL.
Stock researchCompany · Overview
ABCL research
Overview
Company profile and research snapshot.
Company profile
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Stifel | Buy | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 7, 2026 | Benchmark | Buy | — |
| May 5, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 25, 2026
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Benzinga · Aug 12, 2026
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.
SeekingAlpha · Aug 11, 2026
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading
AbCellera pivots to its own pipeline with ABCL635 for menopausal hot flashes. Read the latest analysis on the stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
